#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

Episode 407

0:00-1:59:22

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Michael Davidson is a world-renowned cardiologist, lipidologist, and the founding CEO of NewAmsterdam Pharma. He begins this episode by sharing how his family history shaped his interest in lipidology and primary prevention. He explains why prevention should focus on causal drivers of disease rather than near-term risk and examines the causal relationship between LDL and atherosclerotic cardiovascular disease. Michael then traces the complicated history of CETP inhibitors—from the original rationale that raising HDL would reduce cardiovascular risk to the failures of torcetrapib, dalcetrapib, and evacetrapib—and explains how lessons from these trials ultimately led to the development of obicetrapib. He reviews the phase 2 and phase 3 trials of obicetrapib, its effects on LDL-C, apoB, LDL particle number, and Lp(a), the ongoing cardiovascular outcomes trial, and where the drug could fit alongside statins and other lipid-lowering therapies. Peter and Michael discuss the relationship between statins and diabetes risk, then turn to the potential role of obicetrapib in Alzheimer's disease prevention, exploring the genetics of APOE4 and CETP, cholesterol metabolism within the brain, and emerging biomarker data.

Publisher

The Peter Attia Drive

Link

peterattiamd.com/michaeldavidson/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260914-pod-michaeldavidson&utm_content=260914-pod-michaeldavidson-podfeed

Published

September 14, 2026

Duration

1h 59m

Format

Podcast

Category

Lifestyle · Health & Wellness

Source

RSS feed

Host

Peter Attia, MD

TP

The Peter Attia Drive

@peterattiadrive

#preventingcardiovascular #alzheimersdisease #loweringldlearly

The Nile